![California-based Shape Memory Medical Inc. Secures $38million in series C round funding. This round was led by Earlybird Venture Capital and with the participation of new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P..](https://startuprise.io/wp-content/uploads/2024/03/California-based-Shape-Memory-Medical-Inc.-Secures-38Million-in-Series-C-Round-Funding.webp)
California-based Shape Memory Medical Inc. Secures $38million in series C round funding. This round was led by Earlybird Venture Capital and with the participation of new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P..
Ted Ruppel, president and CEO of Shape Memory Medical said, āWith this financing, we are well positioned to accelerate the clinical and market development of shape memory polymer technology for aortic and peripheral vascular markets,”.
The funds will support the execution of the AAA-SHAPE Pivotal Trial, a randomized controlled study comparing EVAR plus sac management with IMPEDE-FX RapidFill to stand-alone EVAR.
Read also – Lehi-based Qualiti.ai Secures Strategic Investment from Crosslink Capital
The funding will also support the research and development of our product pipeline, and the expansion of sales and marketing strategies to address the increasing demand for our commercially-available IMPEDE Embolization Plug family of devices,ā continued Ruppel.
The Companyās proprietary shape memory polymer is a low-density, porous embolic material that is crimped for catheter delivery and self-expands upon contact with blood for rapid conversion to organized thrombus. The technology offers unique properties including vascular space-filling, radiolucency, low radial force, and stimulation of the immune response and healing system.
The company recently announced that the Food and Drug Administration (FDA) granted investigational device exemption (IDE) for the company to begin a prospective, multicenter, randomized, open-label trial to determine the safety and effectiveness of the IMPEDE-FX RapidFillĀ® Device in improving abdominal aortic aneurysm (AAA) sac behavior, when used with elective endovascular aneurysm repair (EVAR).
Thom Rasche, Partner at Earlybird Venture Capital and the newest addition to the Shape Memory Medical Board commented, āShape Memory Medicalās approach to embolization is highly differentiated. At Earlybird Health, we support companies with breakthrough technologies and robust, positive patient outcomes. With 35 million people worldwide affected by AAA, leading to 150,000-200,000 annual deaths due to rupture, Shape Memory Medicalās innovative concepts for managing aortic aneurysms have the potential to be transformative in treating this condition.ā
About Shape Memory Medical
Shape Memory Medical Inc. is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers, with devices approved in more than 25 countries spanning regions in Asia, the Middle East, Europe, the Americas and Australia.
Read also – CA-based PawCo Secures $2Million in Seed Funding
Neurovascular embolization products include the TrelliXĀ® Embolic Coil, which is CE marked for use in the EU. Peripheral embolization products include the IMPEDEĀ® and IMPEDE-FX Embolization Plugs and IMPEDE-FX RapidFillĀ® Device.